1 **From Vaccine to Pathogen: Modeling Sabin 2 Vaccine Virus Reversion and Evolutionary Epidemiology**

2 Wesley Wong[1*], Jillian Gauld[1*], Michael Famulare[1*]

4 **Author Affiliations**

5   1. Institute for Disease Modeling, Global Good, Intellectual Ventures, Bellevue, WA, USA
6   * Currently employed at the Bill and Melinda Gates Foundation
7

Corresponding Author

Michael Famulare

Building IV, 3150 139th Ave SE, Bellevue, WA 98005

+1 (425) 691-3327

mfamulare@idmod.org

Keywords:

Sabin 2, cVDPV2, poliovirus, genetic reversion, evolution, modeling, vaccine

Classification: BIOLOGICAL SCIENCES: Evolution

Author Contributions

Abstract

The oral poliovirus vaccines (OPV) are one of most effective disease eradication tools in public

health. However, the Sabin 2 vaccine strain can revert attenuation and cause outbreaks of circulating,

vaccine-derived poliovirus (cVDPV2) that are clinically indistinguishable from wild poliovirus (WPV).

Accurately assessing cVDP2 risk requires disentangling the complex interaction between epidemiology

and evolutionary biology. Here, we developed a Sabin 2 reversion model that simulates the reversion of

Sabin 2 to WPV based on the clinical differences in shedding duration and infectiousness between

individuals vaccinated with Sabin 2 and those infected with wild poliovirus. Genetic reversion is

informed by a canonical reversion pathway defined by three gatekeeper mutations (A481G, U2909C,

and U398C) and the accumulation of genetic load from deleterious nonsynonymous mutations. Our

model captures essential aspects of both phenotypic and molecular evolution and simulates

transmission using a multiscale transmission model that consolidates the relationships among immunity,

susceptibility, and transmission risk. We show that despite the rapid reversion of Sabin 2, cVDPV2

outbreaks can be controlled by maintaining high levels of population-level immunity and sanitation.

Supplementary immunization activities must maintain high vaccine coverage to prevent future cVDPV2

outbreaks in the targeted intervention zone, but declining global immunity against Sabin 2 makes them

increasingly risky to implement in poor sanitation regions regardless of historical immunization activity.

A combined strategy of assessing and improving sanitation levels in conjunction with high coverage

vaccination campaigns will limit future cVDPV2 emergence and spread.

Significance Statement

Since the withdrawal of the Sabin 2 oral poliovirus vaccine (OPV2), circulating vaccine-derived

poliovirus outbreaks caused by the genetic reversion of Sabin 2 vaccine virus (cVDPV2) have been

increasing in frequency. The current strategies for combating cVDPV2 involve supplemental

immunization activities with monovalent Sabin 2 oral poliovirus (mOPV2), which can inadvertently seed

future cVDPV2 outbreaks. Accurately assessing future cVDPV2 outbreak risk following mass mOPV2

campaigns is critical poliovirus eradication efforts but must consider the interaction between genetic

reversion and epidemiological transmission. We developed an evolutionary epidemiology model to

integrate Sabin 2 genetic reversion and transmission into a single framework to evaluate their relative

contribution to cVDPV2 outbreaks and inform future intervention strategies.

Introduction

Mass immunization with oral poliovirus vaccine (OPV) has led to a >99.99% drop in wild

poliovirus (WPV) cases (1) and the complete eradication of Type 2 and Type 3 WPV. The OPVs are highly

efficacious vaccines that confer long-lasting protective immunity (2). A curious feature of these vaccines

is that vaccinated individuals can shed and transmit vaccine virus. Vaccine transmission increases

population-level immunity but is problematic when viruses revert attenuation, resulting in circulating,

vaccine-derived poliovirus (cVDPV) capable of causing paralytic poliomyelitis cases clinically

indistinguishable from WPV (3). Following the eradication of Type 2 WPV, the Global Polio Eradication

Initiative coordinated the global withdrawal of Sabin 2 OPV (OPV2) from routine immunization

schedules (commonly referred to as the Switch) to prevent future sources of circulating, vaccine-derived

Type 2 poliovirus (cVDPV2) (1).

Despite the Switch, cVDPV2 outbreaks continue to be a pressing public health concern and have

emerged as a significant issue threatening global poliovirus eradication efforts (1, 4). Although OPV2 is

no longer used in routine immunization, monovalent OPV2 (mOPV2) vaccination campaigns are still

used as supplemental immunization activities (SIAs) to combat cVDPV2 outbreaks. cVDPV2 outbreaks

are now reported throughout the African continent, Pakistan, Afghanistan, China, Malaysia and the

Philippines and 29% of the outbreaks in Africa have involved international spread (4, 5). Since the

Switch, 126 mOPV2 campaigns utilizing more than 300 million doses of OPV2 have been implemented to

control cVDPV2 outbreaks (6). These SIAs are estimated to be responsible for seeding over half of the

cVDPV2 outbreaks observed since the Switch (6). Ensuring the future safety and efficacy of these SIA

campaigns while minimizing the risk of seeding future cVDPV2 outbreaks is critical to the success of the

poliovirus eradication initiative.

The Sabin 2 vaccine strain was derived from a wild-type isolate (P22/P712/56) passaged in

monkey kidney cells to achieve neurovirulence attenuation (7). However, identifying the genetic

mutations responsible for attenuation has been surprisingly complicated, in part because the progenitor

has not been fully sequenced and because P22/P712/56 is thought to be naturally attenuated relative to

other WPV strains (8). Despite this, phylogenetic analyses of whole genome sequences collected from

cVDPV2 outbreaks suggest a common evolutionary pathway to attenuation reversal (9). This pathway is

characterized by the rapid fixation three gatekeeper mutations, A481G, U2909C, and U398C, within the

first few weeks after vaccination (9, 10). All three mutations have previously been implicated as

molecular determinants of attenuation for Sabin 2 (11–14). A481G and U398C are noncoding mutations

that affect the stability of a 5' hairpin structure that mediates translation efficiency (13, 15, 16) and

U2909C is a nonsynonymous mutation in the VP1 capsid protein.

However, genetic reversion is not the sole determinant of cVDPV2 emergence. Environmental

sewer samples have identified revertant strains in regions with no detectable cVDPV2 cases (17). In fact,

vaccinated individuals can shed and transmit revertant viruses to other individuals (10, 18), but whether

this results in clinically-detected cVDPV2 outbreaks depends on the epidemiological context. These

cVDPV2 outbreaks are associated with regions with historically poor vaccination rates and low

population-level immunity (6, 19). Thus, while Sabin 2 reversion is a prerequisite of cVDPV2 emergence,

whether it triggers a public health crisis depends on the interactions between genetic reversion and

local epidemiological conditions.

Mathematical models can be useful tools for assessing cVDPV2 emergence risk and

characterizing the evolutionary and epidemiological factors that allow cVDPV2 outbreaks to occur. We

developed an evolutionary-epidemiology model that simulates Sabin 2 reversion as it is transmitted in

an epidemiological model previously calibrated during an mOPV2 clinical trial performed in Matlab,

Bangladesh (20). The combined model allows us to assess the consequences of vaccine reversion in the

context of an actual epidemiological setting. By unifying evolutionary theory, population genetics, and

epidemiology into a single framework, our study provides a holistic understanding of cVDPV2

emergence as it relates to both genetic reversion and transmission.

Results

Brief model structure overview

We previously developed agent-based multiscale epidemiology model designed to replicate

household community structure and Sabin 2 vaccine transmission during an mOPV2 clinical trial

performed in Matlab, Bangladesh (20, 21). Transmission is contact based and made heterogeneously

depending on household community structure membership (**Figure 1A**). Susceptibility is defined by a

dose-response model that determines the probability of infection given the strain-specific viral

infectiousness, the total viral exposure dose per contact, and the immunity of the recipient host. The

total viral exposure dose is determined by the viral shedding concentration of the infected individual

and the average fecal-oral dose per contact in the population. Immunity is defined by the OPV-

equivalent antibody titer that determines infection probability. Individuals with low immunity upon

infection have longer shedding durations and higher viral shedding titers. Further details of the

epidemiology model are described elsewhere (21, 22).

Here, we developed and integrated a new Sabin 2 reversion model into the multiscale

epidemiology model. Sabin 2 evolution is modeled as a population of multiple viral lineages founded by

a Sabin 2 vaccine virus strain during vaccination. These viral lineages evolve independently and compete

for the limited availability of naïve or low-immunity individuals in the population. Phenotypic evolution

is driven by the reversion of three gatekeeper mutations (A481G, U2909C, and U398C) and the

accumulation of deleterious nonsynonymous mutations generated through mutation and purged

through selection or genetic drift (**Figure 1B**). We assume complete genetic reversion results in a viral

population whose average infectiousness and shedding duration is identical to those of WPV. Due to the

independent acquisition of mutations across different viruses and viral lineages, individual viruses have

different infectiousness and shedding duration phenotypes even after the three gatekeeper mutations

have reverted.

Simulating Sabin 2 molecular evolution

To inform molecular evolution, intra-host substitution rates for the three gatekeeper mutations

were based on estimates previously calculated from 241 Vp1 (viral protein 1) segments from Sabin-like

poliovirus collected during routine surveillance in Nigeria (10, 23). Nonsynonymous and synonymous

substitution rates were calibrated (**SI Appendix**) to a set of whole genome sequences and VP1 capsids

segments isolated from infections from confirmed Sabin 2, Sabin-like, vaccine-derived poliovirus (VDPV)

and cVDPV2 cases (**Figure 2**). One notable feature of poliovirus evolution is the discordance between

short-term evolution following vaccination and long-term evolution after prolonged circulation. Short-

term evolution is dominated by the accumulation of nonsynonymous mutations, as evidenced by the

increased rate of nonsynonymous mutation accumulation in the whole genome sequences during the

first year of evolution (**Figure 2B**), the reduction in the ratio of nonsynonymous to synonymous

mutations over time (**Figure 2D**), and the elevated dN/dS ratios of Sabin-like samples compared to

cVDPV2 samples (**Supplemental Figure 1**).

We hypothesized that the difference between short-term and long-term evolution represents a

shift in the distribution of fitness effects for nonsynonymous mutations. Simulated nonsynonymous

mutations were divided into two categories: deleterious mutations that can cause a reduction in either

infectiousness or shedding duration, and neutral mutations that have no phenotypic effect. Each

category is associated with a different substitution rate and deleterious nonsynonymous mutations are

purged using a recombination-like process that mimics selection and intra-species recombination within

the host (**SI Appendix**). Deleterious nonsynonymous mutations dominate molecular evolution during the

first year of evolution while neutral nonsynonymous mutations dominate molecular evolution after

prolonged circulation (**Figure 2E**).

Simulating Sabin 2 reversion

Genotype-to-phenotype maps for shedding duration were generated by comparing the

shedding duration of naïve individuals vaccinated with Sabin 2 (median 30.3, average 36 days) with

those infected with WPV (median 40.3, average 48 days) (**SI Appendix**). Due to the rapid intra-host

fixation of the three gatekeeper mutations (**Figure 3A**), we assert that reversion during an infection

extends its shedding duration (**Figure 3B**). Prior to any intra-host evolution, the genotype-to-phenotype

map for shedding duration estimates that naïve individuals vaccinated with non-reverted Sabin 2 have a

median shedding duration of 13.5 days (**Figure 3B**, *dashed red line*). The clinically-observed shedding

durations of Sabin 2 vaccinated individuals (**Figure 3B,** *solid red line*) is realized as the average shedding

durations of different viral genotypes composed of unmutated and reverted Sabin 2 viruses

(**Supplemental Table 1**). After vaccination, 7.6% of simulated vaccinated individuals shed non-reverted

Sabin 2 at the end of shedding, 92.4% shed virus with at least one reverted gatekeeper mutation, and

35.2% shed virus with all three gatekeeper mutations reverted. Interestingly, we did not identify a

deleterious cost (reduction in shedding duration) associated with nonsynonymous mutation

accumulation (**SI Appendix**).

The genotype-to-phenotype map describing viral infectiousness was based on clinical

differences of human dose response between Sabin 2 and WPV. Unlike shedding duration, we identified

a small negative effect associated with deleterious nonsynonymous mutations resulting in a reduction in

viral infectiousness (**SI Appendix**). Our model predicts that viral genotypes with no deleterious

nonsynonymous mutations but are reverted at A481G and U2909C are more infectious than typical WPV

strains (**Figure 3C**). Each additional deleterious nonsynonymous mutation reduces infectiousness such

that a viral genotype with all three gatekeeper mutations reverted and nine deleterious mutations is as

infectious as WPV (**Figure 3D**).

Examining the evolutionary epidemiology dynamics of Sabin 2 reversion

To explore how Sabin 2 reversion and transmission interact, we simulated transmission

following an mOPV2 campaign targeting 10% of children under five in a population with 10 times the

fecal-oral dose of Matlab (2.5e-6 grams per contact) five years after vaccination cessation (**Figure 4**).

These epidemics are cyclic (**Figure 4A**) and characterized by boom-bust cycles that eventually stabilize

within the first three years of transmission. Under these conditions, 10% of stochastic replicates failed to

establish stable, endemic transmission. These stochastic replicates failed after the initial expansion wave

collapsed (**Supplemental Figure 2A**). Should transmission recover, the epidemic rebounds and the

proportion of individuals with no immunity (serum neutralizing antibody titer < 8) declines while the

proportion of individuals with high immunity (serum neutralizing antibody titer > 256) increases (**Figure**

4B). Towards the end of the initial epidemic, the proportion of individuals with no immunity begin to

increase due to a combination of new births and the waning of pre-existing immunity and sets up the

conditions for the next wave of infections.

Complete Sabin 2 reversion (**Figure 4C-D**) occurred within the first 200 days of transmission. To

describe the evolutionary dynamics of the simulated viral population, we focused on the expected mean

(the average of the average) phenotype and the variance of the expected mean. While both shedding

duration and infectiousness converged to the WPV phenotype, shedding duration approached it

monotonically while infectiousness exceeded WPV during the first few months of transmission. The

expected means of both phenotypes were not sensitive to changes in infection number. However, the

variance of the expected mean fluctuated over time and was sensitive to epidemiological dynamics. This

variance was smallest at the onset of the epidemic when infection numbers were highest and biggest

around day 400 when infection number was the smallest. The variance of the expected mean was

inversely correlated with total infection number, but its magnitude also depended on the rate with

which the epidemic was increasing or decreasing over time (**Figure 4, Supplemental Figure 3**).

Surprisingly, complete Sabin 2 reversion does not guarantee stable transmission. The

simulations with observed transmission failure did not show a lack of evolutionary fitness: the simulated

viral populations in these simulations had infectiousness and shedding durations equivalent to or

exceeding that of WPV (**Supplemental Figure 2B-C**).

Population-level immunity and hygiene are major constraints of cVDPV2 emergence

We next utilized this model to simulate cVDPV2 emergence and understand risk. Our scenarios

included a point importation of an infant vaccinated with Sabin 2, and a mass vaccination campaign with

up to 80% coverage in children under five years of age. We explored scenarios with fecal oral doses

equal to, five times greater, and 10 times greater than Matlab (**Figure 5**). The fecal oral dose, combined

with the infection-specific, time-dependent viral shedding concentration per gram of stool (22),

determines the total exposure dose per infectious contact. cVDPV2 emergence was defined as an

outbreak significant enough to trigger a warning from passive routine surveillance efforts. However,

because surveillance is not currently simulated, we operationally define cVDPV2 emergence as a

simulation with sustained cVDPV2 transmission for at least three years.

We found zero risk of cVDPV2 emergence following a mass vaccination campaign (**Figure 5A**) or

point importation event (**Figure 5D**) in Matlab with its current fecal oral dose. However, cVDPV2

emergence is possible at higher fecal-oral doses. Under these conditions, cVDPV2 emergence risk

increases with time since vaccination, but is controlled within the community by higher vaccination

coverage. When the fecal-oral dose was five times that of Matlab (1.8e-6 grams per contact), all

vaccination campaigns and point importations immediately after vaccination cessation (year 0) had a

less than 0.05 chance of causing a cVDPV2 emergence (**Figure 5B**). Vaccination campaigns with less than

30% coverage in populations with more than three years of vaccination cessation had the highest risk of

cVDPV2 emergence, with an emergence rate between 20% and 30%. Following point importation,

cVDPV2 emergence risk rises from 0% immediately after cessation to 20% after five years of cessation

(**Figure 5E**).

When the fecal-oral dose was ten times that of Matlab (2.5e-6 grams per contact), high

vaccination coverage could not efficiently prevent cVDPV2 emergence (**Figure 5C**). Immediately after

vaccination cessation, simulations with high vaccination coverage (> 70% coverage) resulted in cVDPV2

emergence 40-50% of the time. All other scenarios had a greater than 60% chance of cVDPV2

emergence. This increases to a greater than 80% chance following a vaccination campaign with less than

30% coverage in populations with more than three years of vaccination cessation. cVDPV2 emergence

risk following a point importation event increases sharply with time since vaccination (**Figure 5F**),

increasing from 5% immediately after cessation to 55% after five years of cessation.

Discussion

cVDPV2 outbreaks are serious public health dilemmas made possible by viral evolution and

exacerbated by epidemiological conditions. By unifying evolutionary and epidemiological theory into a

single framework, our model assesses cVDPV2 emergence risk in relation to changes in shedding

duration and infectiousness associated with vaccine reversion and the constraints to transmission

imposed by immunity, sanitation, and contact structure. To overcome the lack of direct transmission

measurements for Sabin 2 reversion intermediates, we generated genotype-to-phenotype maps for

shedding duration and viral infectiousness by relying on established molecular evolution and population

genetic theory.

Sabin 2 reversion can be viewed as an adaptive process where Sabin 2 must climb up a fitness

landscape to achieve the optimal, WPV-like phenotype. Within the poliovirus virology literature, Sabin 2

is commonly presented as a purely adaptive process where fixed mutations contribute positively to the

emergence of the WPV phenotype (24). However, it is unlikely that all fixed nonsynonymous mutations

are beneficial (25) and viruses must purge deleterious mutations to prevent Muller's Ratchet from

causing an irreversible decline in viral fitness (26, 27). Muller's ratchet can be avoided by engaging in

intra-species or inter-species recombination with Enterovirus C viruses (28) and by altering the

distribution of fitness effects (DOFE) for fixed mutations (29, 30). The latter is based on Fisher's

Geometric Model (FGM) of adaptive evolution, which predicts that mutations with large-phenotypic

effects are unlikely to fixate the closer an organism is to its fitness optimum. Our model incorporates

FGM by attributing large phenotypic effects to the gatekeeper mutations and specifying

nonsynonymous mutation rates so that early adaptive evolution is dominated by deleterious

nonsynonymous mutations while long-term evolution is dominated by neutral ones.

Interestingly, we failed to identify a deleterious cost associated with nonsynonymous mutations

and shedding duration but did identify one associated with nonsynonymous mutations and infectivity.

This finding suggests that there are differences between intra-host and inter-host selection. This could

reflect strong purifying selection induced by the highly competitive intra-host survival dynamics due to

high viral titers. Conversely, the deleterious cost associated with infectiousness could result from the

genetic drift induced by the severe sampling of viral genotypes during person-to-person transmission

(25, 31). Strong genetic drift could weaken the efficacy of purifying selection in removing deleterious

mutations associated with inter-host transmission, but more work is needed to assess differences in

inter- and intra-host selection. The phenotypes we modeled are the consolidation of multiple factors

such as cell invasion, replication, immune evasion, and environmental survival. These subfactors likely

contribute to both shedding duration and infectiousness, but our ability to map molecular evolution to

these subfactors remains limited.

At its core, cVDPV2 emergence is an evolutionary and epidemiological problem that requires a

combined approach to properly assess how the two interact. From an evolutionary perspective, the

availability of susceptible hosts and the distribution of transmissions dictates the strength of genetic

drift. Once the gatekeeper mutations are fixed, the phenotypic stability of the viral population is

maintained as a mutation-selection-drift balance and the range of phenotypic values explored by the

viral population is determined by the total number of infected individuals in the population. From an

epidemiological perspective, Sabin 2 reversion causes infectiousness and shedding duration to rapidly

increase within the first 200 days of vaccination and allow more individuals to become infected. Despite

the emergence of WPV-like viruses in our simulations, complete genetic reversion of Sabin 2 does not

guarantee a cVDPV2 outbreak. Whether these viruses cause a cVDPV2 outbreak requiring public health

intervention depends on population-level immunity and the average viral exposure dose per infectious

contact (4, 6, 22, 32).

The current strategies for controlling cVDPV2 involve implementing aggressive mOPV2 SIA

activities in outbreak response zones and neighboring regions, intensifying routine immunization in

high-risk areas with inactivated polio vaccine (IPV), ensuring a sufficient supply of Sabin 2 OPV for future

eradication strategies, and identifying high cVDPV2 outbreak risk zones (33). Our work clearly shows

that even regions with historically high vaccination rates are prone to cVDPV2 outbreaks if sanitation is

poor. Evaluations of high cVDPV2 outbreak risk regions should include sanitation assessments and utilize

tools designed to measure fecal contamination for other fecal-oral pathogens such as *E. coli* (34). Prior

to mass immunization with OPV2, sanitation assessments should be made to assess the risk of a cVDPV2

outbreak in both the targeted intervention zone and in the surrounding regions. These assessments will

be useful for resource allocation and for determining the minimum coverage needed to prevent future

cVDPV2 outbreaks. Regions with poor sanitation will require aggressive, high-coverage SIA vaccination

campaigns to prevent seeding future cVDPV2 outbreaks.

Sanitation assessments will also help public health officials determine whether additional WASH

(water, sanitation, and hygiene) interventions are needed to supplement ongoing vaccination activity.

Our study reconfirms that there are sanitation regimes defined by high fecal oral doses that is

guaranteed to seed future cVDPV2 outbreaks (22), regardless of vaccination coverage. Although long-

term investments in infrastructure are prohibitively expensive, relatively simple measures such as the

installation of sanitary latrines and drinking water tubewells have been effective at reducing fecal

contamination in Matlab, Bangladesh (35). Optimistically, short-term sanitation interventions may be

effective if implemented similarly to an emergency response campaign (36), especially if they are

targeted at vaccine recipients and their immediate household community members (21).These targeted,

short-term sanitation interventions could alleviate some of the challenges associated with non-

compliance, long-term adherence failure, and poor implementation that reduce the efficacy of standard

WASH interventions (37, 38).

Our model lays the foundations for integrating population genetic theory and epidemiology to

study the evolutionary epidemiology dynamics of rapidly evolving infectious diseases. The success of our

framework hinges on an understanding of a pathogen's evolutionary trajectory as well as the initial and

ending phenotypic states. We anticipate our model will be extended to the novel OPV2 (nOPV2)

candidates (39) as more about their clinical phenotypes and molecular evolution are known. Depending

on how attenuated and evolutionarily stable the novel OPV2 candidates are relative to Sabin 2, mass

nOPV2 vaccination may reduce the need to also control sanitation levels. We also anticipate our model

will be useful for assessing the risks associated with the live-attenuated varicella zoster vaccines, which

also shows strong evidence of attenuation reversion conferred by a commonly accessed evolutionary

pathway (40).

Materials and Methods

Sequencing Data

We downloaded fasta files for the VP1 segments and whole genome sequences of Sabin 2 and

Sabin 2 derived genomes from Genbank. These samples were collected across 102 studies performed in

countries including Egypt, Madagascar, China, Nigeria, the United States, Israel, Switzerland, and the

Democratic Republic of Congo. Multiple sequence alignments were first generated using MUSCLE

(v3.8.31) (41). Sequences were compared to a known Sabin 2 sample (accession ID: AY184220) to

identify and remove insertions. Sequences with long internal gaps (>15 bases) and coverage < 30%

(percentage of called bases) were discarded. Coding sequence alignments from the whole genome

sequences were generated for each of the poliovirus coding regions by generating multiple sequence

alignments for each of the 15 translated protein coding sequences of the poliovirus genome. These

alignments were further filtered to remove samples with < 90% coverage.

A total of 177 whole genome sequences and 1,643 VP1 sequences were retained for analysis.

Samples were classified as Sabin 2, Sabin-Like, VDPV (vaccine-derived poliovirus), iVDPV

(immunodeficiency-related vaccine-derived poliovirus), cVDPV2 based on their original study

classifications. Viruses that displayed <1% VP1 nucleotide sequence difference from the parental Sabin 2

genome were classified as Sabin-lik2 and those with 1-15% nucleotide sequence difference were

classified as VDPV. VDVPVs isolated from immunodeficient individuals were classified as iVDPV while

samples with evidence of having originated from prior transmission are classified as cVDPV2. The whole

genome sample set also included the Lansing and MEF-1 laboratory strains as well as several engineered

Lansing strain derivatives. Accession numbers, classifications, and study origin for each sample are in

Supplemental File 1 and **Supplemental File 2**. FASTA files for the aligned VP1 and whole genome coding

sequences are available on the **Github repository.**

Coding sequence alignments were used to generate a phylogenetic tree using RAxML (v8.2.10)

with a general time reversable CAT (GTRCAT) model (42). Estimates of nonsynonymous and synonymous

mutation counts and dN/dS were based off the RAxML generated phylogenetic tree. Estimates of

nonsynonymous and synonymous mutation counts from the VP1 sequences were counted directly from

the sequence data. Nonsynonymous and synonymous mutation counts for codons with multiple

mutations were averaged across all possible, unweighted evolutionary paths.

Model Description

Defining Genotypes

Genotypes are defined relative to the Sabin-2 genome and defined by the reversion state of

three gatekeeper mutations (A481G, U2909C, and U398C), and the number of newly derived

nonsynonymous and synonymous mutations in the rest of the genome. The Sabin-2 genome is defined

as an array with 6 different mutation classes:

$$G_{S2} = [0, 0, 0, 0, 0, 0]$$

The first three are Boolean flags that indicate the allelic states of A481G, U2909C, and U398C (0 =

unreverted, 1 = reverted). The last three elements represent the total number of deleterious

nonsynonymous, neutral nonsynonymous, and synonymous mutations present in the genome. The

counts in the latter categories exclude the three gatekeeper mutations. Splitting nonsynonymous

mutations into neutral and deleterious simplifies the true distribution of fitness effects and was

necessary to reconcile phenotypic and molecular evolution (**SI Appendix**). These genotypes represent

the consensus sequence of fixed variants within vaccinated and infected individuals.

For evolved poliovirus strains, we use the notation:

$$G_{i,j,k,nonsyn_{del},nonsyn_{neutral},syn}$$

where *i*, *j*, and *k* are replaced with the allelic states of A481G, U209C, and U398C. $nonsyn_{neutral}$,

$nonsyn_{del}$, and syn are replaced with their respective counts or replaced with X if these mutation

classes are irrelevant. For example, $G_{0,0,0,0,0,0}$ is equivalent to the unmutated Sabin-2 vaccine strain (G_{S2})

and $G_{1,1,1,10,2,15}$ is a genotype where all three gatekeeper mutations have reverted and where 10

deleterious nonsynonymous, 2 neutral nonsynonymous, and 15 synonymous mutations have

accumulated.

Genomic evolution: Modeling Sabin 2 molecular evolution

Genomic evolution is modeled using intra-host substitution rates (λ), the fixation of newly

derived mutations within the host, for each mutation class (λ_{A481G}, λ_{U2909C}, λ_{U398C}, λ_{syn},

$\lambda_{nonsyn,del}$, $\lambda_{nonsyn,neutral}$). This substitution rate reflects the true de novo mutation rate, genetic drift,

and selection within the host. This simplification allows us to use a single consensus genome to

represent the fixed mutations present in the intra-host viral population. Each mutation class (the three

gatekeeper mutations, synonymous mutations, deleterious nonsynonymous mutations, and neutral

nonsynonymous mutations) is associated with a substitution rate that describes its expected fixation

time (**Supplemental File 3**).

To accommodate the effects of intra-host competition and recombination, deleterious

nonsynonymous mutation accumulation also depends on a recombination-like mechanism with rate

$\lambda_{recombination}$ that purges deleterious mutations from the genome (26, 28, 43). Intra-host substitution

rates for the gatekeeper mutations were used as described in (10) while λ_{syn},

$\lambda_{nonsyn,del}$, $\lambda_{nonsyn,neutral}$, and $\lambda_{recombination}$ were calibrated to the whole genome sequences and

VP1 segments downloaded from Genbank. Only confirmed Sabin 2, Sabin-Like, VDPV, and cVDPV

samples were used for calibration. All other samples were excluded from calibration. Calibration details

are provided in the **SI Appendix**.

Upon vaccination with Sabin 2, fixation times for all mutation classes are calculated by drawing

from exponential distributions whose rate parameters are defined by the substitution rate of each

mutation class. For the three gatekeeper mutations, these fixation times determine the time to

reversion. For nonsynonymous and synonymous mutations, these fixation times determine the time to

the next substitution event. To prevent Mueller's Ratchet from resulting in infinite deleterious mutation

load, we also draw a time to the next "recombination" event from an exponential distribution defined

by $\lambda_{recombination}$. During each "recombination" event, the model draws a random number from a

discrete, uniform distribution ranging from zero to $n_{nonsyn,deleterious}$, the number of deleterious

nonsynonymous mutations in the genome, to determine the number of deleterious mutations to

remove. Conceptually, this represents purifying selection within the host and allows us to accommodate

the assumed increase in purifying selection as Sabin 2 reverts to cVDPV2. Pseudocode is provided in

Supplemental Figure 4.

Genotype to Phenotype: Mapping molecular genetics to shedding duration and infectiousness

A core assumption of our model is that each of the three gatekeeper mutations contributes to

the final, WPV phenotype proportional to their relative substitution rates. This assumption is based in

part on evolutionary fitness landscape and adaptation theory, which posits that beneficial mutations of

large effect are more likely to be fixed early on when an organism is far the optimal fitness peak on a

simple, non-rugged fitness landscape (29, 44). By definition, attenuated Sabin 2 vaccine strains are far

from the optimal fitness peak for human infection and genetic reversion is the process of climbing the

fitness landscape to reach the optimal, WPV-like phenotype. Because of their fast substitution rate, we

attribute the bulk of phenotypic change to A481G, followed by U2909C, and to a lesser extent U398C.

The ranked ordering of phenotypic effect in our model is supported in the literature. A481G and U2909C

are consistently identified as the primary molecular determinants of reversion in *in vitro* and *in vivo*

studies (11–16). U398C is only occasionally identified by these studies but its recurrent fixation within

the first few months of transmission (9, 10) suggest its adaptive benefit may be too small to be assessed

in laboratory-based assays relative to A481G and U2909C.

Two epidemiologically relevant phenotypes were calculated for each infection based on its

corresponding genotype: 1) shedding duration and 2) infectiousness. Both shedding duration and

infectiousness are based on a previously described poliovirus dose-response model (22). Conceptually,

the shedding duration is analogous to intra-host selection and infectiousness is analogous to inter-host

selection. Details regarding model calibration are deferred to the **SI Appendix**.

We assume shedding duration follows a log-normal survival distribution with the form:

$$P\left(shedding\ at\ t\ \middle|\ N_{ab_{pre}};infected\ at\ t=0\right) \tag{1}$$

$$=\frac{1}{2}\left(1-erf\left(\frac{ln(t)-(M_g-\log(\delta)\log_2(N_{ab_{pre}}))}{\sqrt{2}ln(S_g)}\right)\right)$$

412   where $N_{ab_{pre}}$ is the pre-infection OPV-equivalent antibody titer (22). For each genotype, M_g and S_g are

413   genome-specific parameters that influence the average shedding duration and its standard deviation.

414   The mean of this log-normal distribution is defined by $M_g-\log(\delta)\log_2(N_{ab_{pre}})$ and its standard

415   deviation defined by S_g.

$$M_g=\log(\mu_{S2})+w_{shedding,g} \tag{2}$$

$$S_g=\sigma\sqrt{|1+w_{shedding,g}|} \tag{3}$$

$$w_{shedding,g}=0+s_{dur,A481G}*G_{A481G}+s_{dur,U2909C}*G_{U2909C}+s_{dur,U398C}*G_{U398C} \tag{4}$$

$$+s_{dur,nonsyn_{del}}*n_{nonsyn_{del}}$$

where μ_{S2} is the average shedding duration of a completely unevolved Sabin 2 virus (G_{S2}) in

immunologically naïive individuals ($N_{ab_{pre}}=1$), σ the standard deviation in shedding duration for G_{S2}.

$w_{shedding,g}$ defines the shedding duration fitness of a strain, G_{A481G}, G_{U2909C}, and G_{U398C} refer to the

allelic status of the three gatekeeper mutations, and $s_{dur,A481G}$, $s_{dur,U2909C}$, $s_{dur,U398C}$ are selection

coefficients that describe the change in shedding duration conferred by each of these mutations. Note

that fitness is additive but in log space.

425  Upon infection or vaccination, we randomly draw a shedding duration from a lognormal

426 distribution with mean $M_g - \log(\delta)\log_2(N_{ab_{pre}})$ and standard deviation S_g. A core feature of our

427 shedding duration model is that new gatekeeper mutations arising within the host extends shedding

428 duration. If a new gatekeeper mutation is acquired, the shedding duration is extended:

$$Duration = Duration_{initial} * e^{S_{gateway} + Norm(0,\sigma)\sqrt{S_{gateway}}} \tag{5}$$

$$S_{gateway} \in \{s_{dur,A481G}, s_{dur,U2909C}, s_{dur,U398C}\} \tag{6}$$

431 where $D_{initial}$ is the shedding duration before acquisition of the gatekeeper mutation and $S_{gateway}$ is

432 the shedding duration selection coefficient for the gatekeeper mutation. Note that $Duration_{initial}$ and

433 the increase in shedding duration, $e^{S_{gateway} + Norm(0,\sigma)\sqrt{S_{gateway}}}$, are log-normally distributed and that

434 multiplying two, independent log-normal distributions results in a log-normal distribution whose mean

435 and variance are the sum of the mean and variances of the original distributions. As a result, shedding

436 duration is the summation of multiple, genome-specific shedding durations whose weights are time-

437 dependent and depend on the fixation of A481G, U2909C, U398C and the accumulation of

438 nonsynonymous mutations.

439  Infectiousness is defined by a beta-Poisson model that assumes a single infectious unit is

440 sufficient to start an infection and that multiple infectious units contribute independently to the

441 probability of infection:

$$P(infection|dose, N_{ab}) = 1 - \left(1 + \frac{dose}{\beta_g}\right)^{-\alpha(N_{ab})^{-\gamma}} \tag{7}$$

where α and β_g are parameters for a beta-Poisson function, dose is the viral exposure dose, and γ

captures the reduction in shedding probability with increasing immunity. Altering the β parameter

shifts the beta-poisson function along the x-axis (dose) and altering the α parameter changes its slope.

Differences in infectiousness between Sabin 2 strains and WPV can be modeled using the same α but

with modified β parameters (22). We interpret the β parameter as a measurement of strain infectivity

and define β_g as:

$$\beta_g = \frac{\beta}{\left(1 + s_{inf,A481G}\right)^{G_{A481G}} \left(1 + s_{inf,U2909C}\right)^{G_{U2909C}} \left(1 + s_{inf,U398C}\right)^{G_{U398C}} \left(1 + s_{inf,nonsyn_{del}}\right)^{n_{nonsyn_{del}}}} \tag{8}$$

where β is the strain infectivity parameter for Sabin 2 (22) (assuming no evolution), $s_{inf,A481G}$,

$s_{inf,U2909C}$, $s_{inf,U398C}$, $s_{inf,nonsyn_{del}}$ are selection coefficients denoting the change in infectiousness

conferred by each of the gatekeeper mutations, and $n_{nonsyn_{del}}$ are the number of nonsynonymous

mutations in the genome. Parameter estimates were obtained by comparing the CCID50 between Sabin

2 and WPV (**SI Appendix**). The inferred selection coefficients for the three gatekeeper mutations are

positive (increases infectiousness) while the selection coefficient for deleterious nonsynonymous

mutations was negative (decreases infectiousness). Infectiousness is calculated only at the onset of

either vaccination or infection.

Acknowledgements

We acknowledge all members of the Institute for Disease Modeling, Global Good, and the Bill and

Melinda Gates Foundation for their useful discussion and input. We also acknowledge Adam Lauring and

Andrew Valesano for early manuscript edits and comments.

Funding

Funding was provided by Bill and Melinda Gates through the Global Good Fund. Funders had no role in

the study design, data collection, analysis, interpretation, or writing of the manuscript. The

corresponding author had full access to all the data in our study and had final responsibility for the

decision to submit for publication.

Data Availability

Data and code will be made publicly available at

https://github.com/InstituteforDiseaseModeling/MultiscaleModeling/tree/evo_epistasis upon

publication.

Declaration of Interests

The authors declare no competing interests during the study. WW, JG, and MF were employed by the

funders through the Bill and Melinda Gates Foundation after study completion.

References

1.   F. Khan, *et al.*, rogress Toward Polio Eradication — Worldwide, January 2016–March 2018.

MMWR Morb Mortal Wkly Rep 2019, 524–528 (2018).

2.   A. S. Bandyopadhyay, J. Garon, K. Seib, W. A. Orenstein, Polio vaccination: past, present and

future. *Future Microbiol.* **10**, 791–808 (2015).

3.   H. E. Jenkins, *et al.*, Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria. *N. Engl. J.*

483   *Med.* **362**, 2360–2369 (2010).

484 4. J. Jorba, *et al.*, Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–

485   June 2019. *Morb. Mortal. Wkly. Rep.*, 1024–1028 (2049).

486 5. M. Alleman, *et al.*, Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide July 2019-

487   February 2020. *MMWR Morb Mortal Wkly Re*, 89–495 (2020).

488 6. G. R. Macklin, *et al.*, Evolving epidemiology of poliovirus serotype 2 following withdrawal of the

489   type 2 oral poliovirus vaccine. *Science (80-.).*, eaba1238 (2020).

490 7. J. W. Almond, The attenuation of poliovirus neurovirulence. *Annu. Rev. Microbiol.* **41**, 153–180

491   (1987).

492 8. A. B. Sabin, L. R. Boulger, History of Sabin attenuated poliovirus oral live vaccine strains. *J. Biol.*

493   *Stand.* **1**, 115–118 (1973).

494 9. A. Stern, *et al.*, The Evolutionary Pathway to Virulence of an RNA Virus. *Cell* **169**, 35-46.e19

495   (2017).

496 10. M. Famulare, *et al.*, Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like

497   Poliovirus Isolates in Nigeria. *J. Virol.* **90**, 317–331 (2015).

498 11. O. M. Kew, R. W. Sutter, E. M. de Gourville, W. R. Dowdle, M. A. Pallansch, Vaccine-derived

499   polioviruses and the endgame strategy for global polio eradication. *Annu. Rev. Microbiol.* **59**,

500   587–635 (2005).

501 12. R. J Duintjer Tebbens, *et al.*, Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling

502   the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs). *Risk Anal.* **23** (2013).

503 13. A. R. Muzychenko, *et al.*, Coupled mutations in the 5'-untranslated region of the Sabin poliovirus

strains during in vivo passages: structural and functional implications. *Virus Res.* **21**, 111–122

(1991).

14. K. M. S. de M. Cassemiro, *et al.*, Molecular and Phenotypic Characterization of a Highly Evolved

Type 2 Vaccine-Derived Poliovirus Isolated from Seawater in Brazil, 2014. *PLoS One* **11**,

e0152251–e0152251 (2016).

15. E. A. Simoes, P. Sarnow, An RNA hairpin at the extreme 5' end of the poliovirus RNA

genome modulates viral translation in human cells. *J. Virol.* **65**, 913 LP – 921 (1991).

16. R. B. Ren, E. G. Moss, V. R. Racaniello, Identification of two determinants that attenuate vaccine-

related type 2 poliovirus. *J. Virol.* **65**, 1377–1382 (1991).

17. H. Asghar, *et al.*, Environmental Surveillance for Polioviruses in the Global Polio Eradication

Initiative. *J. Infect. Dis.* **210**, S294–S303 (2014).

18. R. Abraham, P. Minor, G. Dunn, J. F. Modlin, P. L. Ogra, Shedding of Virulent Poliovirus Revertants

during Immunization with Oral Poliovirus Vaccine after Prior Immunization with Inactivated Polio

Vaccine. *J. Infect. Dis.* **168**, 1105–1109 (1993).

19. I. M. Blake, *et al.*, Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.

N. Engl. J. Med. **379**, 834–845 (2018).

20. M. Taniuchi, *et al.*, Community transmission of type 2 poliovirus after cessation of trivalent oral

polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study. *Lancet.*

Infect. Dis. **17**, 1069–1079 (2017).

21. M. Famulare, *et al.*, Community structure mediates Sabin 2 polio vaccine virus transmission.

medRxiv, 2020.07.01.20144501 (2020).

22.   M. Famulare, C. Selinger, K. A. McCarthy, P. A. Eckhoff, G. Chabot-Couture, Assessing the stability

526   of polio eradication after the withdrawal of oral polio vaccine. *PLOS Biol.* **16**, e2002468 (2018).

527   23.   S. Wassilak, *et al.*, Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and

528   widespread circulation in an underimmunized population. *J. Infect. Dis.* **203**, 898–909 (2011).

529   24.   K. M. Thompson, R. J. Duintjer Tebbens, Modeling the dynamics of oral poliovirus vaccine

530   cessation. *J. Infect. Dis.* **210 Suppl**, S475-84 (2014).

531   25.   A. L. Hughes, Near-Neutrality: the Leading Edge of the Neutral Theory of Molecular Evolution.

532   *Ann N Y Acad Sci* **1133**, 162–179 (2008).

533   26.   L. Chao, Fitness of RNA virus decreased by Muller's ratchet. *Nature* **348**, 454–455 (1990).

534   27.   T. Leitner, The Puzzle of HIV Neutral and Selective Evolution. *Mol. Biol. Evol.* **35**, 1355–1358

535   (2018).

536   28.   Y. Xiao, *et al.*, RNA Recombination Enhances Adaptability and Is Required for Virus Spread and

537   Virulence. *Cell Host Microbe* **19**, 493–503 (2016).

538   29.   O. Tenaillon, The Utility of Fisher's Geometric Model in Evolutionary Genetics. *Annu. Rev. Ecol.*

539   *Evol. Syst.* **45**, 179–201 (2014).

540   30.   D. L. Hartl, C. H. Taubes, Towards a theory of evolutionary adaptation. *Genetica* **102–103**, 525–

541   533 (1998).

542   31.   J. T. McCrone, *et al.*, Stochastic processes constrain the within and between host evolution of

543   influenza virus. *Elife* **7**, e35962 (2018).

544   32.   K. A. McCarthy, G. Chabot-Couture, M. Famulare, H. M. Lyons, L. D. Mercer, The risk of type 2

545   oral polio vaccine use in post-cessation outbreak response. *BMC Med.* **15**, 175 (2017).

33. Geneva: World Health Organization, "Strategy for the Response to Type 2 Circulating Vaccine-
Derived Poliovirus 2020–2021: An addendum to the Polio Endgame Strategy 2019-2023" (2020).

34. Y. Wang, *et al.*, Multipathway Quantitative Assessment of Exposure to Fecal Contamination for
Young Children in Low-Income Urban Environments in Accra, Ghana: The SaniPath Analytical
Approach. *Am. J. Trop. Med. Hyg.* **97**, 1009–1019 (2017).

35. K. Zaman, *et al.*, Can cholera 'hotspots' be converted to cholera 'coldspots' in cholera endemic
countries? The Matlab, Bangladesh experience. *Int. J. Infect. Dis.* **95**, 28–31 (2020).

36. T. Yates, J. Allen, M. L. Joseph, D. Lantagne, "Short-term WASH interventions in emergency
responses in low- and middle-income countries" (2017).

37. A. Ramesh, K. Blanchet, J. H. J. Ensink, B. Roberts, Evidence on the Effectiveness of Water,
Sanitation, and Hygiene (WASH) Interventions on Health Outcomes in Humanitarian Crises: A
Systematic Review. *PLoS One* **10**, e0124688–e0124688 (2015).

38. M. Wolfe, M. Kaur, T. Yates, M. Woodin, D. Lantagne, A Systematic Review and Meta-Analysis of
the Association between Water, Sanitation, and Hygiene Exposures and Cholera in Case–Control
Studies. *Am. J. Trop. Med. Hyg.* **99**, 534–545 (2018).

39. P. Van Damme, *et al.*, The safety and immunogenicity of two novel live attenuated monovalent
(serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1
study. *Lancet* **394**, 148–158 (2019).

40. J. Breuer, Molecular Genetic Insights Into Varicella Zoster Virus (VZV), the vOka Vaccine Strain,
and the Pathogenesis of Latency and Reactivation. *J. Infect. Dis.* **218**, S75–S80 (2018).

41. R. C. Edgar, MUSCLE: a multiple sequence alignment method with reduced time and space
complexity. *BMC Bioinformatics* **5**, 113 (2004).

42.   A. Stamatakis, RAxML version 8: a tool for phylogenetic analysis and post-analysis of large

569   phylogenies. *Bioinformatics* **30**, 1312–1313 (2014).

570   43.   M. Bessaud, M.-L. Joffret, B. Blondel, F. Delpeyroux, Exchanges of genomic domains between

571   poliovirus and other cocirculating species C enteroviruses reveal a high degree of plasticity. *Sci.*

572   *Rep.* **6**, 38831 (2016).

573   44.   E. Svensson, R. Calsbeek, *The Adaptive Landscape in Evolutionary Biology* (OUP Oxford, 2012).

Figure 1 Sabin 2 transmission and reversion schematic A) Multiscale epidemiology model. Individuals

are organized into a series of nested, demographic scales defined by households, *baris*/neighborhoods,

and villages that together define the greater region. The *bari* is an intergenerational living arrangement

of closely related individuals specific to Matlab, the study population the epidemiology model was

calibrated to. Conceptually, it is analogous to a neighborhood. Infectious contacts occur at different

rates to individuals in each of these demographic scales. During each infectious contact, infected

individuals transmit a viral dose that depends on their individual viral shedding concentration and the

average fecal oral dose per contact in the population. **B**) Sabin 2 reversion model. Sabin 2 evolution is

modeled as a population of competing viral lineages whose average phenotypic end state distribution is

identical to that of WPV. Reversion is driven by the acquisition of three gatekeeper mutations (A481G,

U2909C, U398C) and the acquisition of deleterious mutations introduced through mutation and purged

through selection.

Figure 2 Molecular evolution. **A**) Phylogenetic tree based on the nonsynonymous mutations from the

177 whole genome sequences used to calibrate our model. Samples were categorized as Sabin 2, Sabin-

Like, vaccine-derived poliovirus isolated from immunocompromised individuals (iVDPV), vaccine-derived

poliovirus (VDPV), and cVDPV2. The other category includes the Lansing and MEF-1 laboratory strains as

well as several engineered strains derived from the Lansing strain. Samples classified as iVDPV or

"other" were excluded from model calibration. **B**) Simulated genome-wide nonsynonymous mutation

accumulation over time (*orange*) compared against those observed in the Sabin 2, Sabin-Like, VDPV, and

cVDPV2 whole genome sequences. **C**) Simulated (*pink*) VP1 mutation (synonymous and

nonsynonymous) accumulation over time compared against the mutation counts observed in 1,643 VP1

segments. **D**) The ratio of nonsynonymous and synonymous mutations throughout the genome over

time. **E**) Simulated genome-wide nonsynonymous counts partitioned into deleterious (*brown*) and

neutral (*grey*). Across all figures, the solid line is the mean simulation outcome and the shaded area

marks the boundaries of the middle 95%. Empirical data is represented by points and colored according

to the legend in panel **A**. Time was calculated by dividing the number of synonymous mutations per

sample by the synonymous substitution rate (3.16E-05 substitutions/bp/day). The insets in **B,C,** and **E**

are close ups of the first year of evolution to better show short-term evolution dynamics.

Figure 3 Phenotypic Evolution A) Cumulative density reversion probability functions for the three

gatekeeper mutations. The solid line is the mean and the shading the 95% confidence interval. **B)**

Shedding duration profile of immunologically naïve individuals infected with Sabin 2, WPV/cVDPV2, and

three different intermediate viral genotypes. The dotted lines are the shedding durations of the initial

viral genotype assuming no further reversion or evolution. The solid line are the shedding durations of

each viral genotype where the reversion of new gatekeeper mutations extends the current shedding

duration. Nonsynonymous mutations have no discernable phenotypic effect with regards to shedding

duration. **C and D)** Viral infectiousness. Each curve shows strain-specific probability of infection given a

single CCID50 dose plotted against immunity. Panel **C** shows infectiousness following the acquisition of

each of the three gatekeeper mutations. Panel **D** emphasizes the role of deleterious nonsynonymous

mutation and shows the infection probability of different viral genotypes with all gatekeeper mutations

and deleterious nonsynonymous mutations count ranging from zero to 35.

Figure 4 Evo-epidemiological dynamics following a mass vaccination campaign targeting 10% of children

under five, five years post-vaccination cessation in Matlab, Bangladesh. Simulations assume 10x the

fecal oral dose in Matlab to ensure stable transmission and conditioned on stable, endemic transmission

for at least three years. **A**) Total number of infected individuals over time. Solid line indicates the mean

and the shading the boundaries of the middle 95% from 200 simulations **B**) Longitudinal immune

profiles for individuals with low immunity (*red*, antibody titer < 8), intermediate immunity (*light blue*,

antibody titer > 8 and < 256), and high immunity (*dark blue*, antibody titer > 256). **C**) Shedding duration

evolution in naïve individuals over time. **D**) Viral infectiousness evolution over time. For panels **B-D**, the

solid line denotes the simulated average and the boundaries the 95% confidence interval around the

mean. For panels **C** and **D**, the dashed black line indicates the average WPV phenotype.

Figure 5 cVDPV2 outbreak risk. cVDPV2 emergence after a mOPV2 vaccination campaign (**A-C**) or

importation of a single infant immunized with Sabin 2 (**D-F**) occurring after up to five years of

vaccination cessation with fecal-oral doses equivalent to (**A/D**), five times greater (**B/E**), and 10 times

greater (**C/F**) than that inferred for Matlab during an mOPV2 clinical trial.

Supplemental Figure 1 dN/dS ratios for Sabin 2-like, cVDPV2, WPV, and iVDPVs.

Supplemental Figure 2 Simulated evolutionary and epidemiology dynamics following a mass

vaccination campaign targeting 10% of children under five, five years post-vaccination cessation in

Matlab, Bangladesh, conditioned on epidemic extinction within the first three years of transmission. **A)**

Total number of infected individuals over time **B)** Infectiousness represented as the probability of

infecting an immunologically naïve individual given single CCID50 unit dose. **C)** Shedding duration in

immunologically naïve individuals. Each line represents a different simulation outcome.

659 **Supplemental Figure 3** The variance of the expected mean (*black*) for shedding duration (**A**) and

660 infectiousness (**B**) compared against infection count (*orange*). The solid orange line is the mean and

661 shading the boundaries of the middle 95 percentile from 200 simulations and identical to **Figure 4A**.

Algorithm 1: Sabin 2 Intra-Host Molecular evolution

Initialization:

Step 1: Set reversion times for unreverted gateway mutations

  for *mutation in A481G, U2909C, U398C* **do**

    | **if** *not reverted* **then**

    | | Draw reversion time, $t_{reversion_{mutation}}$, from Exponential($\lambda_{mutation}$)

    | **end**

  end

Step 2: Set substitution times for non-gateway mutations

  for *mutation in nonsyn$_{del}$, nonsyn$_{neutral}$, syn* **do**

  | Draw substitution time, $t_{subtitution_{mutation}}$, from Exponential($\lambda_{mutation}$)

  end

Step 3: Set recombination time

  Draw recombination time, t_{recomb}, from Exponential(λ_{recomb})

Intra-host Evolution:

while $t_{infection} < t_{shed}$ **do**

    Step 1: Check if unreverted gateway mutations will revert

    for *mutation in A481G, U2909C, U398C* **do**

    | **if** $t_{infection} = t_{reversion_{mutation}}$ **then**

    | | Revert *mutation*

    | **end**

    end

    Step 2: Check if new non-gateway mutations are fixed

    for *mutation in nonsyn$_{del}$, nonsyn$_{neutral}$, syn* **do**

    | **if** $t_{infection} = t_{reversion_{mutation}}$ **then**

    | | Increase mutation count, $n_{mutation}$, by 1

    | | Draw a new $t_{mutation}$ from Exponential($\lambda_{mutation}$)

    end

    Step 3: Check if deleterious nonsynonymous mutations are purged

    if $t_{infection} = t_{recomb}$ **then**

    | Draw X from Uniform(0, $n_{nonsyn_{del}}$)

    | Subtract X from the deleterious nonsynonymous mutation count, $n_{nonsyn_{del}}$

    | Draw a new t_{recomb} from Exponential(λ_{recomb})

end

662
663   **Supplemental Figure 4** Pseudocode for simulating Sabin 2 molecular evolution

Genotype	Proportion	Expected Shedding Duration
Sabin 2 (no reversions)	0.076 (0.059, 0.093)	14.39 (14.08, 14.69)
A481G only	0.186 (0.162, 0.211)	25.46 (24.71, 26.24)
U2909C only	0.024 (0.014, 0.034)	20.39 (19.85, 20.92)
U398C only	0.01 (0.004, 0.016)	18.98 (18.52, 19.47)
A481G + U398C	0.075 (0.059, 0.091)	33.53 (32.46, 34.62)
U398C + U2909C	0.005 (0.001, 0.01)	26.90 (26.10, 27.72)
A481G + U2909C	0.273 (0.247, 0.300)	36.08 (34.93, 37.26)
A481G + U2909C + U398C	0.352 (0.325, 0.382)	47.51 (45.93, 49.174)

Supplemental Table 1 Final viral genotypes in primary vaccine recipients and the expected shedding

durations of individuals infected with these genotypes, assuming no further reversion. Bootstrapped

confidence interval for the mean were calculated from 1000 simulated primary vaccinations, repeated

1000 times. Shedding durations are reported in days. Sabin 2 in this table is defined as a viral genotype

with zero gatekeeper reversions.

Supplemental File 1 Accession numbers and study origins of the whole genome sequences

Supplemental File 2 Accession numbers and study origins of the VP1 segments